Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + olaparib + paclitaxel
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Durvalumab + olaparib + paclitaxel is a combination therapy that brings together three distinct mechanisms of action. Durvalumab is a PD-L1 inhibitor (checkpoint inhibitor), olaparib is a PARP inhibitor, and paclitaxel is a taxane chemotherapy agent. The combination was designed to boost immune response by adding an anti-PD-1 checkpoint inhibitor, as PARP inhibitors are known to increase the expression of PD-L1 protein in tumors. This triplet regimen has shown improved pathological complete response rates in HER2-negative breast cancer, particularly in triple-negative breast cancer and a subset of hormone receptor-positive/HER2-negative patients with MammaPrint ultra-high (MP2) status. The combination has also demonstrated efficacy in advanced endometrial cancer.
- Other names
- durvalumab/olaparib/paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD274 (Programmed cell death protein 1 ligand 1)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on durvalumab + olaparib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + olaparib + paclitaxel.